INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to “Sell”

INmune Bio (NASDAQ:INMB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

INmune Bio Price Performance

INMB stock opened at $1.62 on Friday. The firm has a market capitalization of $43.06 million, a P/E ratio of -0.97 and a beta of 0.97. INmune Bio has a 52-week low of $1.09 and a 52-week high of $3.24. The company’s 50 day simple moving average is $1.55 and its 200-day simple moving average is $1.46.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Investors Weigh In On INmune Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new stake in shares of INmune Bio during the 4th quarter valued at $26,000. Intech Investment Management LLC acquired a new position in shares of INmune Bio in the second quarter worth $26,000. Squarepoint Ops LLC purchased a new stake in shares of INmune Bio during the third quarter worth $30,000. Virtu Financial LLC purchased a new stake in shares of INmune Bio during the fourth quarter worth $32,000. Finally, Wells Fargo & Company MN boosted its position in INmune Bio by 79.0% during the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after purchasing an additional 10,970 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.